PALO ALTO, Calif., May 15, 2019 – Neumentum, a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Scott Shively, Chief Executive Officer, will present at the 2019 BIO International Convention being held June 3 – 6, 2019 in Philadelphia, PA. Mr. Shively will provide an overview of the Company as well as key program progress and updates.

Presentation details are as follows:

Event: 2019 BIO International Conference
Date: June 5, 2019
Time: 11:30 AM EST
Location: Pennsylvania Convention Center; Theater 3

Addressing a National Health Emergency

Neumentum’s lead product candidate, NTM-001 may help address unmet needs for providers, payers and patients, offering effective pain treatment options without some of the potential disadvantages of opioids. America’s opioid crisis has been declared a national public health emergency.

Over 70 million surgical procedures are performed in the U.S. annually and postsurgical pain is routinely treated with opioid analgesics. Yet opioids are associated with side effects – some severe enough to be treatment limiting – and the potential for misuse and abuse. While diversion of opioids is well publicized in the retail setting, it is also a growing problem in the hospital setting, where theft and illegal transfer have become increasingly prevalent.

Every day more than 1,000 people are treated in emergency rooms for misusing prescription opioids.[1] There were more than 17,000 deaths due to prescription opioid pain relievers in 2015, nearly three times the number of deaths in 1999.[2]
The FDA has announced new guidelines in developing non-opioid pain options will be coming in 2019.[3]

About Neumentum

Neumentum is developing and plans to commercialize products that have the potential to effectively treat pain, without the risks of abuse, misuse and diversion seen with opioid analgesics. Neumentum’s lead product candidate, NTM-001 (novel, alcohol-free formulation of ketorolac in a pre-mixed bag for continuous IV infusion), has the potential to treat moderately severe acute pain that requires analgesia at the opioid level for up to 24 hours, usually in a postoperative setting, and to reduce the need for opioids. For more information, visit

# # #

Scott Shively
CEO & Co-founder

Taggart McGurrin, CPA, MBA, JD
FP&A/Business Development Manager

[1] Centers for Disease Control and Prevention, Prescription Opioid Overdose Data.

[2] National Institute on Drug Abuse, Overdose Death Rates. Supporting data.

[3] US Food and Drug Administration, Statement by FDA Commissioner Scott Gottlieb, M.D., on the agency’s ongoing work to forcefully address the opioid crisis.